■要了解治疗模式,医疗保健资源利用(HCCU),美国老年人弥漫性大B细胞淋巴瘤(DLBCL)的经济负担。
■此回顾性数据库分析利用了美国医疗保险和医疗补助服务中心2015年至2020年的医疗保险按服务收费的行政索赔数据来描述DLBCL患者特征,治疗模式,HCCU,以及66岁以上患者的费用。在DLBCL诊断时对患者进行索引,并要求从索引前12个月到索引后3个月连续入组。HCRU和费用(2022年美元)报告为每个患者每月(PPPM)估计。
■共有11,893名患者接受≥1线(L)治疗;1633和391名患者接受≥2L和≥3L治疗,分别。中位数(Q1,Q3)年龄为1L,2L,和3L启动,分别,是76(71,81),77(72,82),77(72,82)年。最常见的治疗是R-CHOP(70.9%)用于1L,苯达莫司汀±利妥昔单抗用于2L(18.7%)和3L(17.4%)。3L中有14.8%的患者使用了CART。总的来说,39.6%(1L),42.1%(2L),47.8%(3L)的患者有全因住院。在1L中,每行的所有原因平均值(中位数[Q1-Q3])成本PPPM为22,060美元(20,121美元[16,676-24,597美元]),2L$30,027($20,868[$13,416-$31,016]),3L和47,064美元(25,689美元[15,555-44,149美元]),增加的成本主要是由住院费用驱动的。有和没有CART的患者的全因3L平均(中位数[Q1-Q3])总费用PPPM为$153,847($100,768[$26,534-$253,630])和$28,466($23,696[$15,466-$39,107]),分别。
■对于患有复发性/难治性DLBCL的老年人,3L治疗没有明确的护理标准。DLBCL的经济负担随着治疗的每个进展而加剧,因此强调需要额外的治疗选择。
UNASSIGNED: To understand treatment patterns, healthcare resource utilization (HCRU), and economic burden of diffuse large B-cell lymphoma (DLBCL) in elderly adults in the US.
UNASSIGNED: This retrospective database analysis utilized US Centers for Medicare and Medicaid Services Medicare fee-for-service administrative claims data from 2015 to 2020 to describe DLBCL patient characteristics, treatment patterns, HCRU, and costs among patients aged ≥66 years. Patients were indexed at DLBCL diagnosis and required to have continuous enrollment from 12 months pre-index until 3 months post-index. HCRU and costs (USD 2022) are reported as per-patient per-month (PPPM) estimates.
UNASSIGNED: A total of 11,893 patients received ≥1-line (L) therapy; 1633 and 391 received ≥2L and ≥3L therapy, respectively. Median (Q1, Q3) age at 1L, 2L, and 3L initiation, respectively, was 76 (71, 81), 77 (72, 82), and 77 (72, 82) years. The most common therapy was R-CHOP (70.9%) for 1L and bendamustine ± rituximab for 2L (18.7%) and 3L (17.4%). CAR T was used by 14.8% of patients in 3L. Overall, 39.6% (1L), 42.1% (2L), and 47.8% (3L) of patients had all-cause hospitalizations. All-cause mean (median [Q1-Q3]) costs PPPM during each line were $22,060 ($20,121 [$16,676-$24,597]) in 1L, $30,027 ($20,868 [$13,416-$31,016]) in 2L, and $47,064 ($25,689 [$15,555-$44,149]) in 3L, with increasing costs driven primarily by inpatient expenses. Total all-cause 3L mean (median [Q1-Q3]) costs PPPM for patients with and without CAR T were $153,847 ($100,768 [$26,534-$253,630]) and $28,466 ($23,696 [$15,466-$39,107]), respectively.
UNASSIGNED: No clear standard of care exists in 3L therapy for older adults with relapsed/refractory DLBCL. The economic burden of DLBCL intensifies with each progressing line of therapy, thus underscoring the need for additional therapeutic options.